Skip to main content
Premium Trial:

Request an Annual Quote

BioMarker Strategies Gets $1.7M in Private Investment

NEW YORK (GenomeWeb News) – BioMarker Strategies has raised $1.7 million through a private funding round that included the Abell Foundation, the Baltimore-based company said today.

BioMarker Strategies is developing a tumor biopsy processing and testing system called SnapPath that is intended to quickly analyze a solid sample at the point of biopsy. It also is developing a series of pathway-based, ex-vivo biomarker tests to help physicians make therapeutic decisions for cancer patients.

The investment came in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. The firm is situated at the Johns Hopkins Science and Technology Park, located in East Baltimore.